Patients with MELD >40 have significantly greater waitlist mortality than patients with MELD = 40.
Introduction
The disparity between the availability of donor organs and the growing number of patients awaiting transplant is one of the greatest challenges in organ transplantation. A needs-based allocation policy prioritizes those at greatest risk of death on the waitlist while a utility-based policy prioritizes graft and patient survival. In 1998, the United States (US) Department of Health and Human Services adopted the Final Rule, which set guidelines for organ allocation based on medical urgency. 1 The goal was to balance equity and utility in the distribution of organs while avoiding futility. The transplant community continues to debate the relative weights of each. In response to the increasing demand for liver transplantation (LT) in an era of organ shortage, there have been several liver allocation policy changes over the past two decades in the US aimed at minimizing waitlist mortality without negatively impacting post-transplant survival. Prior to 1998, patients with end-stage liver disease (ESLD) were stratified by time accumulated on the waitlist and hospital status, with patients in the intensive care unit given the highest priority. 2 In 1998, the United Network for Organ Sharing (UNOS) modified this allocation policy by incorporating the Child-Turcotte-Pugh (CTP) score with the intention of prioritizing patients on the waitlist based on clinical measures of liver dysfunction. However, the system remained flawed because the CTP score required subjective patient assessment, and the emphasis on wait time did not allow the donor organ to be allocated to the patient with the greatest need. 3 On February 27, 2002, UNOS implemented the Model for Endstage Liver Disease (MELD) scoring system, which is based on objective laboratory tests (total bilirubin, international normalized ratio and creatinine) and ranges from 6 (less ill) to 40 (gravely ill). [4] [5] [6] The MELD score changed the liver allocation policy in the US from one primarily driven by wait time to a quantitative severity score that prioritized patients with the greatest waitlist mortality. 7, 8 Although most countries have adopted the MELD system for prioritizing patients for transplant, [9] [10] [11] [12] [13] several countries use other criteria to allocate organs, with or without taking into account the MELD score. [14] [15] [16] [17] [18] In India, liver allocation is based on wait time. 15 In the United Kingdom, it is based on the United Kingdom End-stage Liver Disease Score, which directs organs to candidates who have a realistic chance of surviving more than 5 years post transplantation. 14 In Spain, allocation is based on MELD score with several modifications according to factors such as indication, combined transplants, pediatric recipients, possibility of split, and time on the waitlist. 16 In Japan, candidates are assigned a clinical priority based on blood type, degree of sickness (MELD and CTP score, acute liver failure), and wait time.
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Although patients with greater MELD scores were critically ill, their survival after LT was not inferior compared to the pre-MELD era. 19, 20 The MELD score was arbitrarily capped at 40 based on the presumption that transplanting patients with MELD [40 would be futile. 5 As a result, patients with MELD [40 receive the same priority as patients with MELD = 40, differentiated only by their time on the waitlist (Fig. S1 ). There is no maximum MELD that excludes patients from receiving a LT, 21 and the decision to delist candidates is institution-specific. Despite the cap at 40, the number of patients transplanted with MELD [40 has increased by nearly 3-fold since 2002 ( Fig. 1 ) with regional differences, the greatest rates seen in Organ Procurement and Transplantation Network (OPTN) Regions 5 and 7 (Fig. 2) . Since the implementation of the MELD for liver allocation, several modifications have been made to further reduce waitlist mortality. One modification in the US grants additional MELD ''exception" points to patients with specific diseases (e.g. hepatocellular carcinoma [HCC] , hepatopulmonary syndrome) who have low risk of short-term mortality, but require LT prior to developing irreversible complications. 22, 23 These candidates then receive priority based on the exception MELD, which is often a value much higher than the calculated MELD. Patients awaiting combined liver-intestine transplant also receive MELD exception points, with patients less than 18-years of age receiving 23 additional points to their calculated Pediatric End-stage Liver Disease (PELD) scores without being capped at 40 due to their high waitlist mortality. 24 Currently, more than half of the pediatric patients on the waitlist are transplanted using exception scores because the calculated PELD often fails to capture mortality risk appropriately. The rising number of adult patients granted MELD exception points in the US has caused an increase in allocation MELD score (the MELD elevator effect) by pushing patients listed with MELD scores based solely on laboratory values to require higher and higher scores to be competitive for transplant in many regions of the country. In Brazil, in addition to HCC and primary liver tumors, patients with complications such as refractory ascites, pruritus, persistent or recurrent hepatic encephalopathy, and recurrent cholangitis are considered special situations and may be granted MELD exception points when severe. 12 In the Euro-transplant system (Germany, Belgium, Croatia, Luxemburg, Netherlands, Austria, Hungary, and Slovenia), MELD exception points are given to patients with pulmonary complications of cirrhosis, recurrent cholangitis in cholestatic liver disease, or HCC within the Milan criteria.
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Another modification in the US was the implementation of ''Share 35" on June 17, 2013, which prioritized patients with MELD P35 within the donor's OPTN region before any local candidates with MELD \35. The intention was to allow broader distribution of livers to expedite transplantation of the sickest patients in OPTN regions. The goal was more equitable distribution of organs to patients most in need by eliminating local donor service area (DSA) priority that had previously impaired such access. Recent studies have shown that Share 35 has been associated with more transplants, fewer organ discards, and lower waitlist mortality without compromising post-transplant outcomes. [25] [26] [27] Finally, on January 11, 2016, serum sodium was added into the MELD score based on studies demonstrating better prediction of waitlist mortality compared to the MELD score alone. [28] [29] [30] [31] [32] [33] In the US, these modifications to the liver allocation scheme have focused on prioritizing the sickest patients for LT, calling into question the MELD cap at 40. To determine the effect of capping the MELD, we used OPTN data to analyze the waitlist mortality and post-transplant outcomes of adult patients with MELD [40 compared to patients with MELD = 40. We hypothesized that the MELD cap of 40 disadvantages the sickest patients with ESLD and that rank ordering by calculated MELD score may decrease waitlist mortality and provide survival benefit to patients with the greatest MELD scores.
Methods and materials

Patients
With permission, data were obtained from the UNOS Standard Transplant Analysis and Research File, which included pre-transplant, transplant and follow-up data from the OPTN database, supplemented by the mortality information from the Social Security Death Master File. We analyzed all adult candidates (age P18 years) who were listed for LT from February 27, 2002 (date of implementation of MELD) until December 31, 2012 to allow for 3-year follow-up for all transplanted patients. Excluded from the analyses were patients listed as status 1A (candidates with sudden and severe onset of liver failure with a very short life expectancy without LT), recipients of dual organ transplantation (other than kidney), patients with MELD exception points, recipients of living donor LT, and patients with incomplete data (Fig. 3) . Thirty-day waitlist survival was selected due to the continued high mortality rate of patients with MELD P40 after 14 days.
Statistical analyses
Analyses were performed to estimate overall survival (OS) of patients on the LT waitlist, post-transplant OS (Post-TX-OS), and to assess whether waitlist OS or Post-TX-OS varied among patients with MELD P40. In addition, analyses were conducted to evaluate the benefit of having a LT for patients with different MELD scores. For the OS of waitlist patients who reached a MELD P40, we focused on 15-and 30-day survivals because, once candidates reached a MELD P40, their mortality was quite high after 30 days without transplant. OS of waitlist patients with a MELD P40 were analyzed in the following ways: 1) Patients whose MELD reached P40 at any time during waitlist registration. OS was defined as the time between the date of first reported MELD P40 during waitlist registration and the date of death or removal from waitlist due to ''too sick for transplant". Patients who received a transplant were censored at the time of transplant. 28, 34 The analysis focused on the first 30 days after patients had a first reported MELD P40. OS probabilities within 30 days after the first reported MELD P40 were calculated using the product-limit method with Greenwood standard errors and were plotted for patients with MELD = 40, 41-44, 45-49, and P50. Waitlist patients who died on the same day of a reported MELD P40 were excluded from this analysis.
2) Patients who were registered on the waitlist with an initial MELD P40. OS was defined as the time from the date of initial waitlist registration to the date of death or removal from waitlist due to ''too sick for transplant". 3) Cox regression analysis, with MELD as a time-dependent covariate, to estimate the hazard ratio (HR) of death for patients according to the MELD score at each time point, all compared to the corresponding group of patients with MELD = 40. Smoothing splines 35 were used to illustrate the relative risk of death of patients with different MELD scores. 4) Cumulative incidence analyses to estimate the proportion of patients who received a LT and the proportion of patients who died on the waitlist in each MELD category, with LT or death on the waitlist considered as two competing events. This analysis used the same group of patients as in analysis 1.
For the analyses of Post-TX-OS, we focused on the first 3 years after transplant. Post-TX-OS was defined as time from transplant to date of death or date of the last follow-up. Post-TX-OS probabilities were calculated using the Kaplan-Meier method with Greenwood standard errors, and were plotted for patients transplanted at MELD = 40, 41-44, 45-49, or P50. Cox regression models were used to estimate the HR of death for patients transplanted at MELD [40 compared to the group of patients transplanted at MELD = 40. Transplant benefit was determined using a Cox regression model for survival from date of waitlist registration, with MELD and LT as time-dependent covariates, and HRs were calculated for patients receiving a LT compared to those who did not for the first 30 days or the first 90 days from date of waitlist registration.
All statistical analyses were performed in STATA (Version 11.2, StataCorp, College Station, Texas). A p value of \0.05 was considered statistically significant.
For further details regarding the materials used, please refer to the CTAT table.
Results
Patient characteristics
A total of 65,776 candidates on the waitlist and 30,369 LT recipients were included in the analysis. Patient characteristics are shown in Table 1 . The median age was 53 with the majority being Caucasian men with blood types O and A. Among the 2,615 (8.6%) who had capped MELD scores of 40 at the time of transplant, 2,169 (83%) had calculated MELD scores [40. Characteristics of patients on the waitlist with MELD P40 at time of waitlist registration and those transplanted with MELD P40 are shown in Table 2 . 
Waitlist and post-transplant survival
Using data on changes in MELD for patients registered on the waitlist, with MELD treated as a time-dependent covariate, analyses showed that compared to MELD = 40, the relative risk of death within 30 days after waitlist registration (as measured by the HR) increased monotonically as MELD increased from 20 to 40 and continued to increase as MELD went above 40 (Fig. 4) . Fig. 5B . The two figures show very similar patterns, demonstrating that waitlist survival rates decreased dramatically as MELD score increased above 40 (p \0.001). At day 15, after patients had a first reported MELD P40, the estimated OS rates were 58% (95% CI: 55-61%) for patients with MELD = 40 and decreased to 49% (95% CI: 47-52%) for MELD 41-44, 37% (95% CI: 34-41%) for MELD 45-49, and 28% (95% CI: 23-34%) for MELD P50 (Fig. 5B) . Similar differences were observed at day 30 with the estimated OS rates being 33% (95% CI: 29-37%) for patients with MELD = 40, 29% (95% CI: 26-31%) for MELD 41-44, 19% (95% CI: 15-23%) for MELD 45-59, and 17% (95% CI: 12-23%) for MELD P50.
Post-TX-OS rates at 1 and 3 years for patients transplanted with MELD [40 were not significantly different compared to MELD = 40 (p = 0.43) (Fig. 5C) . One-year Post-TX-OS rates were 83% (95% CI: 79-86%) for MELD = 40, 80% (95% CI: 78-82%) for MELD 41-44, 79% (95% CI: 76-82%) for MELD 45-49, and 78% (95% CI: 70-83%) for MELD P50. Three-year Post-TX-OS rates were also similar among the four groups. Compared to MELD = 40, the HR of death within the first 3 years posttransplant was 1.0 (95% CI: 0.8-1.3) for patients transplanted at MELD 41-44, 1.1 (95% CI: 0.9-1.4) for MELD 45-49, and 1.1 (95% CI: 0.8-1.5) for MELD P50.
Impact of transplant on survival for waitlisted patients
Among patients with MELD P40, the cumulative incidence rates of LT decreased as the MELD increased, while the cumulative incidence rates of deaths on the waitlist increased. By day 30, the cumulative incidence rates of transplant were 60% (95% CI: 58-63%), 54% (53-56%), 46 (44-49%), and 34% (95% CI: 30-39%) for patients with MELD = 40, 41-44, 45-49, and P50, respectively, and the cumulative incidence rates of death on the waitlist were 33% (95% CI: 31-36%), 40% (95% CI: 38-41%), 49% (95% CI: 47-52%), and 60% (95% CI: 55-65%), respectively.
Significant transplant survival benefit was seen at MELD [20, and the magnitude of transplant benefit increased with increasing MELD score (Table 3) 
Discussion
In 2015, 11,951 adult patients in the US were added to the LT waitlist, 6,230 underwent cadaveric LT, and 2,917 were removed due to death or being too sick for transplant (https://optn.transplant.hrsa.gov), illustrating how the allocation of livers is complicated by an organ supply that cannot meet the present need. In the current system in the US, all patients with MELD scores of 40 and greater are listed at 40 (not their actual calculated MELD scores) and ranked by time on the waitlist at that score. Patients thus stop accruing MELD points once they reach a score of 40 despite the escalating risk of death on the waitlist. Our study is the first to evaluate waitlist outcomes of patients with MELD [40 compared to patients with MELD = 40. We demonstrate that the relative risk of death on the LT waitlist does not stabilize at MELD = 40, but rather increases as the calculated MELD score increases above 40. Patients with MELD 45-49 are 2.6 times more likely to die, and patients with MELD P50 are 5.0 times more likely to die on the waitlist compared to patients with MELD = 40. Uncapping the MELD score is the first step toward better determination of the sickest patients for urgent organ allocation.
Once patients reach a MELD [20, there is a significant benefit to LT that increases with the MELD score, and there is no MELD score above which LT seems futile. Despite concerns about futility at MELD [40, at least 200 such patients per year were transplanted over the study period, and mortality HR continued to favor transplant in patients with MELD [40. Importantly, there were no significant differences in 1-and 3-year survival rates after LT for patients with MELD [40 when compared to patients with MELD = 40. A recent study analysing LT candidates following the implementation of Share 35 also demonstrated similar post-transplant outcomes in patients transplanted with MELD P40; however, waitlist outcomes were not analysed in this study. 36 Despite the similarity in survival rates after LT among the four MELD groups (40, 41-44, 45-49, P50 ) and the greater survival benefit of LT for patients with MELD 45-49 or P50 compared to MELD = 40, we were able to demonstrate that a smaller proportion of patients in the higher MELD categories received LT compared to patients in the lower MELD groups under the current LT allocation policy. Therefore, a capped MELD score misrepresents the medical urgency of LT and disadvantages a substantial and growing group of patients with ESLD. The number of patients transplanted with MELD [40 increased over the study period and likely will continue to increase, attributable to improvements in the pre-transplant care of critically ill patients. 37, 38 Patients with MELD P40 represented 8.6% of all patients transplanted during the study period, of which 83% had MELD scores [40. The large regional variation in the distribution of patients with MELD [40 in the US may partly explain institutional differences in thresholds to care for and transplant high MELD patients. In addition, where a patient lives in the US affects their likelihood of receiving a LT because of regional variation in population demographics, prevalence of liver disease, organ donation rates, transplant center acceptance rates, and median MELD at transplant. In certain regions of the country (OPTN region 10), the median transplant MELD is as low as 20, whereas in region 5 (California and surrounding states) the median transplant MELD is 31, accounting for the highest percentage of patients being transplanted with MELD P40 (Fig. 2 ). These and other regional differences such as use of MELD exception points contribute to the problem of unequal access to LT in the US. Liver redistricting is currently being evaluated and may help level geographic disparity in the US. 39 Over the past two decades, efforts have focused on lowering waitlist mortality without compromising post-transplant out- White  61  61  56  60  65  63  59  59  Black  15  14  14  16  10  10  11  12  Hispanic  18  18  22  15  21  21  22  20  Asian  5  6  6  7  3  5  6  7  Other  1  1  2  2  1  1 The overall survival and post-transplant survival probabilities were calculated using the Kaplan-Meier method, and confidence intervals were based on Greenwood standard errors. Data for age is median (range). CI, confidence interval; ICU, intensive care unit; MELD, Model for End-stage Liver Disease; n.a., not available; NASH, non-alcoholic steatohepatitis; OPTN, Organ procurement and transplant network; sCr, serum creatinine; SLK, simultaneous liver-kidney.
comes. Nonetheless, it can be difficult to identify candidates who are too sick for LT to prevent futile transplants. 40 Implementation of the MELD was the first and most important change in liver allocation, redirecting donor organs to the sickest patients and decreasing waitlist mortality. 19, [41] [42] [43] [44] To allow broader distribution of livers to patients with the greatest medical urgency and further decrease waitlist mortality, Share 35 and MELD sodium were recently introduced in the US. 25 that ultimately determines organ allocation in most countries, including the US. The strength of our study is the use of a large national transplant registry of patients (n = 65,776 patients registered and n = 30,369 patients transplanted) over a ten-year period with three years of follow-up, which allowed us to conduct whole population-based analyses to examine the liver allocation strategy while minimizing potential sample bias. The limitations are the retrospective design and that factors relating to a patient's suitability for transplantation or to a center's decision to accept or reject a liver allograft, both of which affect graft and patient survival, were not accounted for in the analysis. Despite these limitations, the study results have important implications for improving the current liver allocation policy.
As long as there is a shortage of donor organs, any organ allocation system will disadvantage a subgroup of patients on the waitlist for transplantation. Despite improvements in the current liver allocation system, patients with the greatest waitlist mortality do not receive appropriate priority for LT, and policy makers must critically evaluate the MELD cap at 40. Analysis of OPTN data suggests that uncapping the MELD may further decrease waitlist mortality, preserve post-transplant outcomes, and provide transplant benefit to patients with the greatest MELD scores. We advocate uncapping the MELD score to allow more equitable distribution of livers and to better align the current liver allocation policy with the fundamental principle of prioritizing the patients most in need. Hazard ratios (HR) and p values for post-transplant mortality risk based on MELD score at transplant compared to mortality risk of patients on the waitlist with the same MELD score. MELD subgroup for patients on waitlist was a time-dependent covariate in the Cox regression analyses. For patients who received transplant, MELD at transplant was used for the follow-up time post-transplant. HR \1 indicates that there is decreased mortality (and therefore, increased survival benefit) associated with transplant over the first 30 and 90 days post-transplant. Transplant benefit was determined using a Cox regression model for survival from date of waitlist registration, with MELD and LT as time-dependent covariates, and HRs were calculated for patients receiving a LT compared to those who did not for the first 30 days or the first 90 days from date of waitlist registration. CI, confidence interval; HR, hazard ratio; LT, liver transplant; MELD, Model for End-Stage Liver Disease.
